MicroRNA-451a downregulation in liraglutide-treated individuals with diabetes: A potential cardiovascular protective mechanism.

Diab Vasc Dis Res · 2024 · PMC11437537 · PMID 39325062

Europe PMC DOI

hedged sentence

0.1100

closest p · 2.2× alpha

0.1100

boldest claim

The sentences

failed to reach statistical significancep = .11not close (p > 0.1)

N terminal-pro B-type natriuretic peptide (NT-proBNP) tended to decrease from baseline to week eight in participants who received liraglutide, although the difference failed to reach statistical significance (410.13 ± 602.32 pg/mL vs 305.81 ± 485.35 pg/mL, p = .11).

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.